Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LaNova Australia Pty Limited
• Treatments: Antibodies

Criteria

Key Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

2. Histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.

3. At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.

4. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose

Key Exclusion Criteria:

1. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤grade 1 of CTCAE v5.0

2. Uncontrolled tumour-related pain

3. Known central nervous system (CNS)

4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

5. Use of inhaled corticosteroids

6. Known history of autoimmune disease

7. Use of any live attenuated vaccines within 28 days

8. Have severe cardiovascular disease

9. Uncontrolled or severe illness

10. History of immunodeficiency disease

11. Active malignancies which are likely to require the treatment.

12. Child-bearing potential female

13. Have psychiatric illness or disorders

Note: Other protocol defined Inclusion/Exclusion criteria may apply.